» Articles » PMID: 30830275

External Validation of a Nomogram for the Prediction of 10-year Life Expectancy in Candidates for Radical Prostatectomy

Overview
Journal World J Urol
Specialty Urology
Date 2019 Mar 5
PMID 30830275
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Accurate life expectancy prediction is essential in decision-making concerning treatment of clinically localized prostate cancer (PCa). Nomogram predictions are more precise and reproducible than clinician's estimations. The most accurate nomogram addressing 10-year life expectancy in PCa patients has not been externally validated to date. Therefore, we aimed to evaluate the performance of this nomogram in a contemporary external cohort.

Patients And Methods: For this, we enrolled all consecutive patients, who underwent radical prostatectomy at a single institution between 2005 and 2007. Age at surgery and Charlson Comorbidity Index (CCI) were assessed. PCa-related deaths and patients under 55 years were excluded as indicated by the nomogram. The prediction of 10-year life expectancy was calculated according to the nomogram and compared to actual survival data. Calibration and discrimination were assessed using calibration plots.

Results: Overall, 1597 patients were evaluated, with a median age of 64 years (range 55-78 years) at surgery and a median follow-up of 134.4 months (range 0.1-161.7 months). Median CCI was 0 (range 0-10). At 10 years, 134 patients (8.4%) had died of other causes than PCa. The nomogram showed moderate discrimination capacities on receiver-operator characteristic analysis (c-index: 0.64). On calibration curves, the nomogram underestimated the actual life expectancy.

Conclusion: The performance accuracy of this prediction model was moderate and underestimated 10-year life expectancy of contemporary PCa patients. In conclusion, prediction of life expectancy remains challenging with a continued need for more precise tools.

Citing Articles

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network.

Rescigno P, Maruzzo M, Rebuzzi S, Murianni V, Cinausero M, Lipari H Oncologist. 2022; 27(12):e949-e956.

PMID: 35920559 PMC: 9732238. DOI: 10.1093/oncolo/oyac147.


Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Lin Y, Huang Y, Liu C, Lee T, Chen M, Chien Y Front Pharmacol. 2021; 12:669236.

PMID: 34084142 PMC: 8167063. DOI: 10.3389/fphar.2021.669236.

References
1.
Leung K, Hopman W, Kawakami J . Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Can Urol Assoc J. 2012; 6(5):367-73. PMC: 3478337. DOI: 10.5489/cuaj.11161. View

2.
Ross P, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani P . Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 2002; 20(2):82-8. DOI: 10.1053/suro.2002.32490. View

3.
Hall W, Jani A, Ryu J, Narayan S, Vijayakumar S . The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8(1):22-30. DOI: 10.1038/sj.pcan.4500772. View

4.
Kent M, Penson D, Albertsen P, Goodman M, Hamilton A, Stanford J . Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Med. 2016; 14:25. PMC: 4748497. DOI: 10.1186/s12916-016-0572-z. View

5.
Kent M, Vickers A . A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer. J Urol. 2014; 193(6):1938-42. PMC: 4502577. DOI: 10.1016/j.juro.2014.11.082. View